



May 30, 2017

Genomic Health Announces Presentation of Eight Oncotype DX® Studies at the 2017 American Society of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types

Presentations in Breast and Prostate Cancers Highlight Ability of Tests to Answer Critical Clinical Questions and Optimize Treatment Outcomes

REDWOOD CITY, Calif., May 30, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from eight Oncotype DX® studies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place June 2-6 at McCormick Place in Chicago. These presentations represent data across multiple tumor types including invasive breast, ductal carcinoma in situ (DCIS), prostate and renal cancers.

"Precision medicine is dependent on validated tests that provide insight into the biology of an individual's cancer and actionability into busy healthcare practices," said [Phil Febbo, M.D.](#), chief medical officer, Genomic Health. "As evidenced by our upcoming data presentations at ASCO, our suite of Oncotype DX tests continue to deliver outstanding value to patients, providers and global healthcare systems."

ASCO abstracts are now available at <http://abstracts.asco.org/>. Following are details for each presentation (all times are in Central Daylight Time):

Saturday, June 3

- | Abstract: 11568
Poster Presentation: "SEER study of breast cancer specific mortality (BCSM) in patients with lobular tumors treated based on recurrence score results."
Authors: Baehner FL, Shak S, Miller DP, Petkov VI.
Location: Hall A
Time: 1:15 - 4:45 p.m.

Sunday, June 4

- | Abstract: 528
Poster Presentation: "Refined estimates of local recurrence risks and the impact of the DCIS score adjusting for clinico-pathological features: Meta-analysis of E5194 and Ontario DCIS cohort studies."
Authors: Rakovitch E, Gray RJ, Baehner FL, Miller DP, Sutradhar R, Crager M, Gu S, Nofech-Mozes S, Badve SS, Hanna W, Hughes LL, Wood WC, Paszat LF, Shak S, Sparano JA, Solin LJ.
Location: Hall A
Time: 8 - 11:30 a.m.
- | Abstract: 537
Poster Presentation: "The performance of the 21-gene assay standard cutpoints of 18 and 31 in HR+, HER2- invasive breast cancer (BC), while waiting for TAILORx mid-range recurrence score results."
Authors: Miller DP, Petkov VI, Shak S.
Location: Hall A
Time: 8 - 11:30 a.m.
- | Abstract: 543
Poster Presentation: "Clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions incorporated the 21-gene recurrence score (RS): Elderly (≥70 yrs) vs younger patients (Pts)."
Authors: Stemmer SM, Steiner M, Rizel S, Baruch NB, Soussan-Gutman L, Bareket-Samish A, Nisenbaum B, Isaacs K, Fried G, Rosengarten O, Peretz T, Svedman C, McCullough D, Klang S, Zidan J, Ryvo L, Kaufman B, Shak S, Liebermann N, Geffen DB.
Location: Hall A
Time: 8 - 11:30 a.m.

Monday, June 5

| Abstract: 4508

Oral Presentation: "Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients."

Authors: Escudier BJ, Rini BI, Martini J-F, Chang WY-H, Breza J, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, English PA, Li R, Lin X, Valota O, Carteni G, Staehler MD, Motzer RJ, Ravaud A.

Location: Arie Crown Theater

Time: 8 - 11 a.m.

| Abstract: 504

Oral Presentation: "Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer."

Authors: Harbeck N, Gluz O, Clemens MR, Malter W, Reimer T, Nuding B, Aktas B, Stefek A, Pollmanns A, Lorenz-Salehi F, Uleer C, Krabisch P, Kummel S, Liedtke C, Shak S, Wuerstlein R, Christgen M, Kates R, Kreipe HH, Nitz U.

Location: Hall D2

Time: 9:45 a.m. - 12:45 p.m.

| Abstract: 5063

Poster Presentation: "A 17-gene panel for prediction of adverse surgical pathology in the setting of MRI-guided prostate biopsy."

Authors: Salmasi A, Said JW, Raman S, Shindel AW, McCullough D, Bailey H, Rothney M, Marks LS, Febbo PG, Reiter RE.

Location: Hall A

Time: 1:15 - 4:45 p.m.

| Abstract: 5074

Poster Presentation: "Association of risk of clinical recurrence (CR) and prostate cancer death (PCD) with a 17-gene genomic prostate score (GPS) value < 20."

Authors: Febbo PG, Crager M, Burke E, Lawrence HJ, Cullen J, Klein EA.

Location: Hall A

Time: 1:15 - 4:45 p.m.

About Oncotype DX[®]

The Oncotype DX[®] portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score[®], has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score[™] predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score[™] predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention. With more than 750,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatment.org.

About Genomic Health

[Genomic Health](http://www.GenomicHealth.com), Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its

Oncotype IQ[®] Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 750,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ[®] Liquid Select[™] test. The company is based in [Redwood City](http://www.RedwoodCity.com), California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: [@GenomicHealth](https://twitter.com/GenomicHealth), [Facebook](https://www.facebook.com/GenomicHealth), [YouTube](https://www.youtube.com/GenomicHealth) and [LinkedIn](https://www.linkedin.com/company/GenomicHealth).

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our business model; the applicability of clinical study results to actual outcomes; the impact of results from clinical studies on market adoption of Oncotype DX tests; unanticipated costs or delays in research and development efforts; and other risks and uncertainties set forth in our filings with the Securities and Exchange Commission, including our most recent report on Form 10-Q for the quarter ended March 31, 2017. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, Liquid Select, Genomic Prostate Score, Oncotype DX AR-V7 Nucleus Detect and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

GHDX-B



To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/genomic-health-announces-presentation-of-eight-oncotype-dx-studies-at-the-2017-american-society-of-clinical-oncology-annual-meeting-reinforcing-unique-impact-across-cancer-types-300464914.html>

SOURCE Genomic Health, Inc.

News Provided by Acquire Media